(HealthDay News) — For patients with end-stage renal disease (ESRD), receipt of hemodialysis (HD) is associated with increased mortality after radiofrequency ablation (RFA) for hepatocellular carcinoma, according to a study published online in the Journal of Gastroenterology and Hepatology.
Masaya Sato, from the University of Tokyo, and colleagues used a nationwide database to examine in-hospital mortality and hemorrhagic complications following RFA among patients on HD for ESRD. For each patient enrolled, up to 4 non-dialyzed patients were randomly selected. The authors compared in-hospital mortality and hemorrhagic complications between dialyzed and non-dialyzed patients (437 and 1345 patients, respectively) following RFA.
The researchers found that mortality was significantly lower in those aged ≤70 years vs older patients (P=.02). Dialyzed ESRD patients had significantly higher in-hospital mortality than non-dialyzed patients (1.1% vs 0.15%; odds ratio, 7.77; P<.001). There was a significant difference in hemorrhagic complications between dialyzed ESRD and non-dialyzed patients (3.4% and 0.87%, respectively; odds ratio, 4.75; P<.001).
“In-hospital mortality following RFA was higher in dialyzed ESRD patients than in non-dialyzed patients,” the authors write. “The indications for RFA in dialysis-dependent patients should be considered carefully.”
- Sato M, Tateishi R, Yasunaga H, et al. Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: a nationwide survey. J Gastroenterol Hepatol. 7 March 2017. doi: 10.1111/jgh.13780